Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — ASX SMIDcaps Conference 2025
12 slides from Lumos Diagnostics's conference presentation, Sep 24, 2025
Slide 1: ASX Announcement: ASX SMIDcaps 2025 Conference - Presentation
ASX ANNOUNCEMENT ASX SMIDcaps 2025 Conference - Presentation For personal use only MELBOURNE, Australia (24 September 2025) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, has today lodged a presentation to be delivered by Barrie L
Slide 2: Media and Investor Contacts
Media Contacts: Haley Chartres – Australia H^CK Director haley@hck.digital +61 423 139 163 Investor Contact: George Kopsiaftis IR Specialist, IR Department ir@lumosdiagnostics.com +61 409 392 687 For personal use only Company Registered Office: Lumos Diagnostics Holdings Ltd Suite 2, Level 11 385 Bo
Slide 3: Lumos Diagnostics Holdings Limited ASX SMIDcaps Conference
For personal use only Lumos Diagnostics Holdings Limited ASX SMIDcaps Conference 24 September 2025 Financial information is shown in USD unless otherwise stated. www.lumosdiagnostics.com © Lumos Diagnostics . All rights reserved. 1
Slide 4: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of For personal use
Slide 5: Lumos develops, manufactures and distributes innovative diagnostic products
For personal use only Lumos develops, manufactures and distributes innovative diagnostic products – delivering actionable information, in real time, at the point-of-care. © Lumos Diagnostics , all rights reserved 3
Slide 6: Lumos Business Overview
Lumos Business Overview For personal use only COMMERCIAL SERVICES PRODUCTS Development Contract Manufacturing FebriDx® Women’s Health People and capability drive value - able to leverage R&D, IP, manufacturing scale, medical, quality and regulatory skillset across Lumos’ Products and Commercial Serv
Slide 7: Financials Summary
Financials Summary Revenue (US$M) Gross Profit (US$M) & Margin % Adjusted EBITDA (US$M) For personal use only 13.0 10.0 100%0.0 $12.4 FY23 FY24 FY25 12.5 $7.8 8.0 $7.1 80% -1.0 12.0 $6.0 11.5 6.0 60% -2.0 $11.1 64.0% 62.9% 40% -3.0 57.1% 11.0 4.0 $10.5 10.5 -4.0 -$3.4 2.0 20% -$3.9 10.0 -5.0 9.5 0.0
Slide 8: LDX Recent Achievements
LDX Recent Achievements FebriDx® Journey To Transform The Practice Of Medicine For personal use only Study completed Future Events and submitted to FDA Oct 2025 FebriDx pediatric study to commence Valued at Aug 2025 US$317m over CLIA waiver 6 years with application submission Nov 2025 – Feb 2026 Sec
Slide 9: The Unmet Medical Need – Respiratory Infections in Primary Care
The Unmet Medical Need – Respiratory Infections in Primary Care “Patients want answers. Doctors need certainty. FebriDx® delivers both.” For personal use only FebriDx® point of care test solution FebriDx® Supports Antibiotic Stewardship and Helps Combat Antimicrobial Resistance Of antibiotic prescri
Slide 10: Key Priorities
For personal use only Key Priorities FDA decision on the CLIA Implement agreement with Initiate FebriDx® pediatric Deliver on Hologic fFN Progress to formal product waiver for FebriDx® is PHASE Scientific, advance study in October – fully development milestones - development on the first expected be
Slide 11: Investor Takeaways
Investor Takeaways For personal use only $ First in Class Product FebriDx® Nearing Major Transformational US$317M (A$487M) Revenue Growth & Margin Strength US Breakthrough Distribution Deal • FY25 revenue up 11% to US$12.4M; product sales • CLIA waiver study exceeded performance targets • With PHASE
Slide 12: Investor Briefing Thank You
For personal use only Lumos Diagnostics Holdings Limited Investor Briefing Thank You www.lumosdiagnostics.com © Lumos Diagnostics . All rights reserved. 10
Lumos Diagnostics Holdings — ASX SMIDcaps Conference 2025 on 6ix